Frequency of undetected CYP2D6 hybrid genes in clinical samples: Impact on phenotype prediction

Drug Metabolism and Disposition

Volumn 40, Issue 1, 2012, Pages 111-119

  Black III, John Logan ^a   Walker, Denise L ^a   O'Kane, Dennis J ^a   Harmandayan, Maria ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; CYPD2D6 GENE; CYPD2D7 GENE; DNA SEQUENCE; GENE DELETION; GENE DOSAGE; GENE DUPLICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HYBRID GENE; INTRON; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL;

CHIMERA; CYTOCHROME P-450 CYP2D6; FORECASTING; GENE FREQUENCY; HUMANS; PHENOTYPE;

EID: 84455163168     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040832     Document Type: Article

References (25)

1. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, and Fuhr U (2010) Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 88:643-651.
2. Bapiro TE, Hasler JA, Ridderström M, and Masimirembwa CM (2002) The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol 64:1387-1398. (Pubitemid 35248255)
3. Black JL 3rd, O'Kane DJ, and Mrazek DA (2007) The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin Drug Metab Toxicol 3:21-31. (Pubitemid 47307454)
4. Chida M, Ariyoshi N, Yokoi T, Nemoto N, Inaba M, Kinoshita M, and Kamataki T (2002) New allelic arrangement CYP2D6*36x2 found in a Japanese poor metabolizer of debrisoquine. Pharmacogenetics 12:659-662. (Pubitemid 36005676)
5. Gaedigk A, Bradford LD, Alander SW, and Leeder JS (2006) CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 34:563-569.
6. Gaedigk A, Fuhr U, Johnson C, Bérard LA, Bradford D, and Leeder JS (2010a) CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11:43-53.
7. Gaedigk A, Jaime LK, Bertino JS Jr, Berard A, Pratt VM, Bradford LD, and Leeder J (2010b) Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants. Front Pharmacol doi:10.3389/fphar.2010.00121.
8. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, and Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242.
9. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121. (Pubitemid 47555336)
10. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318.
11. Hosono N, Kato M, Kiyotani K, Mushiroda T, Takata S, Sato H, Amitani H, Tsuchiya Y, Yamazaki K, Tsunoda T, et al. (2009) CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin Chem 55:1546-1554.
12. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
13. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, and Brockmöller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473. (Pubitemid 38903502)
14. Kramer WE, Walker DL, O'Kane DJ, Mrazek DA, Fisher PK, Dukek BA, Bruflat JK, and Black JL (2009) CYP2D6: novel genomic structures and alleles. Pharmacogenet Genomics 19:813-822.
15. Løvlie R, Daly AK, Matre GE, Molven A, and Steen VM (2001) Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 11:45-55. (Pubitemid 32108661)
16. Malhotra AK, Murphy GM Jr, and Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796. (Pubitemid 38625331)
17. Murphy GM Jr, Kremer C, Rodrigues HE, and Schatzberg AF (2003) Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160:1830-1835. (Pubitemid 41103318)
18. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, and Zanger UM (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577-581.
19. Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, Schwab M, and Zanger UM (2004) A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76:128-138. (Pubitemid 39013403)
20. Soyama A, Saito Y, Ohno Y, Komamura K, Kamakura S, Kitakaze M, Tomoike H, Ozawa S, and Sawada J (2006) Diverse structures of chimeric CYP-REP7/6-containing CYP2D6 and a novel defective CYP2D6 haplotype harboring single-type*36 and CYP-REP7/6 in Japanese. Drug Metab Pharmacokinet 21:395-405.
21. Steen VM, Molven A, Aarskog NK, and Gulbrandsen AK (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet 4:2251-2257.
22. Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, and Leucht S (2004) Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 50:1623-1633. (Pubitemid 39121231)
23. Topić E, Stefanović M, Ivanisević AM, Blazinić F, Culav J, and Skocilić Z (2000) CYP2D6 genotyping in patients on psychoactive drug therapy. Clin Chem Lab Med 38:921-927.
24. Yu A, Kneller BM, Rettie AE, and Haining RL (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:1291-1300. (Pubitemid 35424416)
25. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585. (Pubitemid 32953583)